<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">jofin</journal-id><journal-title-group><journal-title xml:lang="ru">Журнал инфектологии</journal-title><trans-title-group xml:lang="en"><trans-title>Journal Infectology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-6732</issn><publisher><publisher-name>IPO “АIDSSPbR"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.22625/2072-6732-2024-16-3-96-104</article-id><article-id custom-type="elpub" pub-id-type="custom">jofin-1667</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Содержание TGF-β1 в сыворотке крови у детей при новой коронавирусной инфекции COVID-19</article-title><trans-title-group xml:lang="en"><trans-title>Blood serum TGF-β1 content in children with new coronavirus infection</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Богомолова</surname><given-names>И. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Bogomolova</surname><given-names>I. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Богомолова Ирина Кимовна – заведующая кафедрой педиатрии лечебного и стоматологического факультетов, д.м.н., профессор</p><p>тел.: 8(3022)35-43-24 доб. 164 </p><p> Чита </p></bio><bio xml:lang="en"><p> Chita</p></bio><email xlink:type="simple">bogomolova_ik@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перегоедова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Peregoedova</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Перегоедова Валентина Николаевна – доцент кафедры педиатрии лечебного и стоматологического факультетов, к.м.н.</p><p>тел.: 8(3022)35-43-24 доб. 164 </p><p>Чита </p></bio><bio xml:lang="en"><p> Chita</p></bio><email xlink:type="simple">v.peregoedova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Читинская государственная медицинская академия</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Chita State Medical Academy</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>22</day><month>09</month><year>2024</year></pub-date><volume>16</volume><issue>3</issue><fpage>96</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Богомолова И.К., Перегоедова В.Н., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Богомолова И.К., Перегоедова В.Н.</copyright-holder><copyright-holder xml:lang="en">Bogomolova I.K., Peregoedova V.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.niidi.ru/jofin/article/view/1667">https://journal.niidi.ru/jofin/article/view/1667</self-uri><abstract><p>Нарушение продукции TGF-β1 сыворотки крови является одним из предполагаемых механизмов новой коронавирусной инфекции 2019 г. (COVID-19).Цель: изучить содержание TGF-β1 сыворотки крови детей при новой коронавирусной инфекции COVID-19.Материалы и методы: одноцентровое одномоментное исследование проведено среди детей от 0 до 17 лет: 119 пациентов с COVID-19 (46,2% (55/119) девочек, 53,8% (64/119) мальчиков) и сопоставлено со 118 здоровыми детьми (53,4% (63/118) девочек, 46,6% (55/118) мальчиков) в качестве контрольной группы. Исследование проведено с апреля по июль 2020 г. Медиана возраста пациентов с новой коронавирусной инфекцией COVID-19 составила 11,0 [9,8; 11,0], здоровых детей – 11,0 [10,1; 11,0] лет. Дети с новой коронавирусной инфекцией COVID-19 разделены на подгруппы с бессимптомной (n=23), легкой (n=61) и среднетяжелой (n=35) формами. Образцы сыворотки на анализ концентрации TGF-β1 взяты у всех пациентов и определены методом проточной флюориметрии.Результаты: независимо от формы тяжести медиана уровня TGF-β1 сыворотки крови детей 0–17 лет с новой коронавирусной инфекцией COVID-19 составила 1340,8 [1340,5; 1632,8] пг/мл, что статистически значимо выше, чем в контрольной группе 8,7 [8,3; 17,0] пг/мл (p&lt;0,001). Сывороточная концентрация TGF-β1 у детей до 6 лет с COVID-19 увеличена относительно школьников (1722,6 [1720,5; 2516,3] против 1231,3 [1229,9; 1487,9] пг/мл, p=0,006). Дети 0–6 лет со среднетяжелой формой COVID-19 имели высокие показатели TGF-β1 сыворотки крови (1896,3 [1876,1; 3329,9] пг/мл) при сравнении с пациентами 7–17 лет (1139,4 [1138,1; 1526,7]; p=0,023).Заключение: повышенные уровни TGF-β1 сыворотки крови зарегистрированы у детей с COVID-19 как при бессимптомной форме, так и с симптомами новой коронавирусной инфекции COVID-19, достигая максимальных значений при среднетяжелой форме у детей 0–6 лет.</p></abstract><trans-abstract xml:lang="en"><p>Impaired serum TGF-β1 production is one of the proposed mechanisms for coronavirus disease 2019 (COVID-19).Study objective: to study blood serum TGF-β1 content in children with new coronavirus infection.Materials and methods: a one-stage study was conducted in 119 patients with COVID-19 and compared with 118 healthy children of the same age and sex as a control group. The age range in both groups was 11.0 years. Preschoolers (0–6 years old) and schoolchildren (7–17 years old) in the group with COVID-19 were 21 (18%) and 98 (82%), respectively. Children with COVID-19 were divided into asymptomatic (n=23), mild (n=61), and moderate (n=35) subgroups. Serum samples for TGF-β1 concentration analysis were taken from all patients and tested by flow fluorimetry. The data were processed using the IBM SPSS Statistics Version 25.0 software package (International Business Machines Corporation, license No Z125-3301-14, USA).Results: median serum TGF-β1 levels of children 0–17 years old with COVID-19 regardless of the form of severity were significantly higher than in the control group. The serum concentration of TGF-β1 in children with COVID-19 of preschool age was increased comparing to schoolchildren. Children 0-6 years old with a moderate form of coronavirus infection had high serum TGF-β1 values when compared with school-age patients.Conclusion: elevated serum TGF-β1 levels were found in children both without clinical manifestations and with symptoms of coronavirus infection, reaching maximum values in the moderate form in children 0–6 years old.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>новая коронавирусная инфекция</kwd><kwd>COVID-19</kwd><kwd>TGF-β1</kwd><kwd>цитокин</kwd><kwd>SARS-CoV-2</kwd><kwd>дети</kwd><kwd>форма тяжести</kwd><kwd>возраст</kwd></kwd-group><kwd-group xml:lang="en"><kwd>new coronavirus infection</kwd><kwd>COVID-19</kwd><kwd>TGF-β1</kwd><kwd>cytokines</kwd><kwd>SARS-CoV-2</kwd><kwd>children</kwd><kwd>severity form</kwd><kwd>age</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Carvacho I, Piesche M. RGD-binding integrins and TGF-β in SARS-CoV-2 infections – novel targets to treat COVID-19 patients? Clin Transl Immunology. 2021 Mar 18;10(3):e1240. DOI: 10.1002/cti2.1240.</mixed-citation><mixed-citation xml:lang="en">Carvacho I, Piesche M. RGD-binding integrins and TGF-β in SARS-CoV-2 infections – novel targets to treat COVID-19 patients? Clin Transl Immunology. 2021 Mar 18;10(3):e1240. DOI: 10.1002/cti2.1240.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Saito A, Horie M, Nagase T. TGF-β Signaling in Lung Health and Disease. Int J Mol Sci. 2018 Aug 20;19(8):2460. DOI: 10.3390/ijms19082460.</mixed-citation><mixed-citation xml:lang="en">Saito A, Horie M, Nagase T. TGF-β Signaling in Lung Health and Disease. Int J Mol Sci. 2018 Aug 20;19(8):2460. DOI: 10.3390/ijms19082460.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Thomas BJ, Kan-O K, Loveland KL, et al. In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β. Am J Respir Cell Mol Biol. 2016 Dec;55(6):759-766. DOI: 10.1165/rcmb.2016-0248PS.</mixed-citation><mixed-citation xml:lang="en">Thomas BJ, Kan-O K, Loveland KL, et al. In the Shadow of Fibrosis: Innate Immune Suppression Mediated by Transforming Growth Factor-β. Am J Respir Cell Mol Biol. 2016 Dec;55(6):759-766. DOI: 10.1165/rcmb.2016-0248PS.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vaz de Paula CB, Nagashima S, Liberalesso V, et al. COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis. Int J Mol Sci. 2021 Dec 24;23(1):168. DOI: 10.3390/ijms23010168.</mixed-citation><mixed-citation xml:lang="en">Vaz de Paula CB, Nagashima S, Liberalesso V, et al. COVID-19: Immunohistochemical Analysis of TGF-β Signaling Pathways in Pulmonary Fibrosis. Int J Mol Sci. 2021 Dec 24;23(1):168. DOI: 10.3390/ijms23010168.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Worthington JJ, Klementowicz JE, Travis MA. TGFβ: a sleeping giant awoken by integrins. Trends Biochem Sci. 2011 Jan;36(1):47-54. DOI: 10.1016/j.tibs.2010.08.002.</mixed-citation><mixed-citation xml:lang="en">Worthington JJ, Klementowicz JE, Travis MA. TGFβ: a sleeping giant awoken by integrins. Trends Biochem Sci. 2011 Jan;36(1):47-54. DOI: 10.1016/j.tibs.2010.08.002.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Denney L, Branchett W, Gregory LG, et al. Epithelialderived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection. Mucosal Immunol. 2018 Mar;11(2):523-535. DOI: 10.1038/mi.2017.77.</mixed-citation><mixed-citation xml:lang="en">Denney L, Branchett W, Gregory LG, et al. Epithelialderived TGF-β1 acts as a pro-viral factor in the lung during influenza A infection. Mucosal Immunol. 2018 Mar;11(2):523-535. DOI: 10.1038/mi.2017.77.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Schultz-Cherry S, Hinshaw VS. Influenza virus neuraminidase activates latent transforming growth factor beta. J Virol. 1996 Dec;70(12):8624-9. DOI: 10.1128/JVI.70.12.8624-8629.1996.</mixed-citation><mixed-citation xml:lang="en">Schultz-Cherry S, Hinshaw VS. Influenza virus neuraminidase activates latent transforming growth factor beta. J Virol. 1996 Dec;70(12):8624-9. DOI: 10.1128/JVI.70.12.8624-8629.1996.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Montalvo Villalba MC, Valdés Ramírez O, Muné Jimé- nez M, et al. Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients. Clin Immunol. 2020 Nov;220:108576. DOI: 10.1016/j.clim.2020.108576.</mixed-citation><mixed-citation xml:lang="en">Montalvo Villalba MC, Valdés Ramírez O, Muné Jimé-nez M, et al. Interferon gamma, TGF-β1 and RANTES expression in upper airway samples from SARS-CoV-2 infected patients. Clin Immunol. 2020 Nov;220:108576. DOI: 10.1016/j.clim.2020.108576.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Colarusso C, Maglio A, Terlizzi M, et al. Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β. Biomedicines. 2021 Dec 17;9(12):1931. DOI: 10.3390/biomedicines9121931.</mixed-citation><mixed-citation xml:lang="en">Colarusso C, Maglio A, Terlizzi M, et al. Post-COVID-19 Patients Who Develop Lung Fibrotic-like Changes Have Lower Circulating Levels of IFN-β but Higher Levels of IL-1α and TGF-β. Biomedicines. 2021 Dec 17;9(12):1931. DOI: 10.3390/biomedicines9121931.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ferreira-Gomes M, Kruglov A, Durek P, et al. SARSCoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat Commun. 2021 Mar 30;12(1):1961. DOI: 10.1038/s41467-021-22210-3.</mixed-citation><mixed-citation xml:lang="en">Ferreira-Gomes M, Kruglov A, Durek P, et al. SARSCoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself. Nat Commun. 2021 Mar 30;12(1):1961. DOI: 10.1038/s41467-021-22210-3.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Shen WX, Luo RC, Wang JQ, Chen ZS. Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. Front Public Health. 2021 May 24;9:671788. DOI: 10.3389/fpubh.2021.671788.</mixed-citation><mixed-citation xml:lang="en">Shen WX, Luo RC, Wang JQ, Chen ZS. Features of Cytokine Storm Identified by Distinguishing Clinical Manifestations in COVID-19. Front Public Health. 2021 May 24;9:671788. DOI: 10.3389/fpubh.2021.671788.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Matsumura S, Shibakusa T, Fujikawa T, et al. Increase in transforming growth factor-beta in the brain during infection is related to fever, not depression of spontaneous motor activity. Neuroscience. 2007;144(3):1133–1140. DOI: 10.1016/j.neuroscience.2006.10.037.</mixed-citation><mixed-citation xml:lang="en">Matsumura S, Shibakusa T, Fujikawa T, et al. Increase in transforming growth factor-beta in the brain during infection is related to fever, not depression of spontaneous motor activity. Neuroscience. 2007;144(3):1133–1140. DOI: 10.1016/j.neuroscience.2006.10.037.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Sheng J, Chen W, Zhu HJ. The immune suppressive function of transforming growth factor-β (TGF-β) in human diseases. Growth Factors. 2015;33(2):92–101. DOI: 10.3109/08977194.2015.1010645.</mixed-citation><mixed-citation xml:lang="en">Sheng J, Chen W, Zhu HJ. The immune suppressive function of transforming growth factor-β (TGF-β) in human diseases. Growth Factors. 2015;33(2):92–101. DOI: 10.3109/08977194.2015.1010645.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int J Biol Sci. 2020;16(11):1954–1955. DOI: 10.7150/ijbs.46891.</mixed-citation><mixed-citation xml:lang="en">Chen W. A potential treatment of COVID-19 with TGF-β blockade. Int J Biol Sci. 2020;16(11):1954–1955. DOI: 10.7150/ijbs.46891.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gheblawi M, Wang K, Viveiros A, et al. AngiotensinConverting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8;126(10):1456-1474. DOI: 10.1161/CIRCRESAHA.120.317015.</mixed-citation><mixed-citation xml:lang="en">Gheblawi M, Wang K, Viveiros A, et al. AngiotensinConverting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020 May 8;126(10):1456-1474. DOI: 10.1161/CIRCRESAHA.120.317015.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Han JS, Choi BS, Yang CW, Kim YS. Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci. 2009 Jan;24 Suppl(Suppl 1):S195-203. DOI: 10.3346/jkms.2009.24.S1.S195.</mixed-citation><mixed-citation xml:lang="en">Han JS, Choi BS, Yang CW, Kim YS. Aldosterone-induced TGF-beta1 expression is regulated by mitogen-activated protein kinases and activator protein-1 in mesangial cells. J Korean Med Sci. 2009 Jan;24 Suppl(Suppl 1):S195-203. DOI: 10.3346/jkms.2009.24.S1.S195.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Boumaza A, Gay L, Mezouar S., et al. Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis. Preprint at https://wwwbiorxivorg/content/10.1101/2020.09.17.300996v1 2020, (10.1101/2020.09.17.300996).</mixed-citation><mixed-citation xml:lang="en">Boumaza A, Gay L, Mezouar S., et al. Monocytes and macrophages, targets of SARS-CoV-2: the clue for Covid-19 immunoparalysis. Preprint at https://wwwbiorxivorg/content/10.1101/2020.09.17.300996v1 2020, (10.1101/2020.09.17.300996).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Sanjabi S, Oh SA, Li MO. Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection. Cold Spring Harb Perspect Biol. 2017 Jun 1;9(6):a022236. DOI: 10.1101/cshperspect.a022236.</mixed-citation><mixed-citation xml:lang="en">Sanjabi S, Oh SA, Li MO. Regulation of the Immune Response by TGF-β: From Conception to Autoimmunity and Infection. Cold Spring Harb Perspect Biol. 2017 Jun 1;9(6):a022236. DOI: 10.1101/cshperspect.a022236.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">O’Sullivan MJ, Mitchel JA, Mwase C, et al. In well-differentiated primary human bronchial epithelial cells, TGF-β1 and TGF-β2 induce expression of furin. Am J Physiol Lung Cell Mol Physiol. 2021 Feb 1;320(2):L246-L253. DOI: 10.1152/ajplung.00423.2020.</mixed-citation><mixed-citation xml:lang="en">O’Sullivan MJ, Mitchel JA, Mwase C, et al. In well-differentiated primary human bronchial epithelial cells, TGF-β1 and TGF-β2 induce expression of furin. Am J Physiol Lung Cell Mol Physiol. 2021 Feb 1;320(2):L246-L253. DOI: 10.1152/ajplung.00423.2020.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Karadeniz H, Avanoğlu Güler A, Özger HS, et al. The Prognostic Value of Lung Injury and Fibrosis Markers, KL-6, TGF-β1, FGF-2 in COVID-19 Patients. Biomark Insights. 2022 Nov 7;17:11772719221135443. DOI: 10.1177/11772719221135443.</mixed-citation><mixed-citation xml:lang="en">Karadeniz H, Avanoğlu Güler A, Özger HS, et al. The Prognostic Value of Lung Injury and Fibrosis Markers, KL-6, TGF-β1, FGF-2 in COVID-19 Patients. Biomark Insights. 2022 Nov 7;17:11772719221135443. DOI: 10.1177/11772719221135443.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Laloglu E., Alay H. Role of transforming growth factorbeta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung injury: A prospective, observational, cohort study. Rev. Soc. Bras. Med. Trop. 2022;55:e06152021. DOI: 10.1590/0037-8682-0615-2021.</mixed-citation><mixed-citation xml:lang="en">Laloglu E., Alay H. Role of transforming growth factorbeta 1 and connective tissue growth factor levels in coronavirus disease-2019-related lung injury: A prospective, observational, cohort study. Rev. Soc. Bras. Med. Trop. 2022;55:e06152021. DOI: 10.1590/0037-8682-0615-2021.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Wang EY, Chen H, Sun BQ, et al. Serum levels of the IgA isotype switch factor TGF-ü1 are elevated in patients with COVID-19. FEBS Lett. 2021 Jul;595(13):1819-1824. DOI: 10.1002/1873-3468.14104.</mixed-citation><mixed-citation xml:lang="en">Wang EY, Chen H, Sun BQ, et al. Serum levels of the IgA isotype switch factor TGF-β1 are elevated in patients with COVID-19. FEBS Lett. 2021 Jul;595(13):1819-1824. DOI: 10.1002/1873-3468.14104.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Maranatha D, Hasan H, Bakhtiar A, et al. Association of TNF-α, TGF-β1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19. J Infect Public Health. 2022 Aug 24;15(10):1072-1075. DOI: 10.1016/j.jiph.2022.08.007.</mixed-citation><mixed-citation xml:lang="en">Maranatha D, Hasan H, Bakhtiar A, et al. Association of TNF-α, TGF-β1, amphiregulin, IL-2, and EGFR WITH pulmonary fibrosis in COVID-19. J Infect Public Health. 2022 Aug 24;15(10):1072-1075. DOI: 10.1016/j.jiph.2022.08.007.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
